Product Images Lanthanum Carbonate

This appears to be a table showing the difference in phosphorus reduction when taking different doses of Lanthanum Carbonate, compared to a placebo. The different doses shown are 225 mg, 675 mg, 1350 mg, and 2250 mg. It is not clear what units the "difference in phosphorus reduction" is measured in, nor is there any other context or information provided to give more meaning to this table.*

This is a medication label for a bottle of chewable tablets used for treating hyperphosphatemia. The tablets contain 500 mg of lanthanum as lanthanum carbonate hydrate and should be chewed or crushed before swallowing. The medication should be taken with or immediately after meals. The label provides additional information for patients and pharmacists, including instructions and storage details. This medication is distributed by Prasco Laboratories in Mason, OH, USA, and is a product of Italy.*

This is a description of a medication named Qymanaco L containing 750mg of Lanthanum (arbonate manufactured by Coosasicon phsunc. The medication is distributed in 6 bottles, with 15 chewable tablets in every bottle designed to be used as a one-month therapy. Patients are advised to chew, or crush the tablets before swallowing, and take them with, or immediately after a meal. The packaging should not be broken, and pharmacists should follow the prescribing instructions of the doctor. Full prescribing information can be found in the package insert.*

This is a description of Lanthanum Carbonate chewable tablets. Each tablet contains 1000mg of Lanthanum Carbonate and should not be swallowed whole. The tablets should be chewed or crushed and taken with or immediately after meals. The package contains 9 bottles, each with 10 chewable tablets, designed for one month's therapy. The inactive ingredients in the tablet include colloidal silicon dioxide, dextrates, and magnesium stearate. The text also includes dosage information, storage conditions, and manufacturer details.*